Belgia - engelsk - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

eg sa-nv - everolimus 5 mg - tablet - 5 mg - everolimus 5 mg - everolimus

Belgia - engelsk - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

krka d.d. novo mesto d.d. - everolimus 5 mg - tablet - 5 mg - everolimus 5 mg - everolimus

Belgia - engelsk - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

sandoz sa-nv - everolimus 5 mg - tablet - 5 mg - everolimus 5 mg - everolimus

Belgia - engelsk - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

teva pharma belgium sa-nv - everolimus 5 mg - tablet - 5 mg - everolimus 5 mg - everolimus

Australia - engelsk - Department of Health (Therapeutic Goods Administration)

pharmacor pty ltd - everolimus, quantity: 0.5 mg - tablet, uncoated - excipient ingredients: butylated hydroxytoluene; crospovidone; ethanol absolute; hypromellose; lactose monohydrate; lactose; acetone; magnesium stearate - everolimus is indicated for the prophylaxis of organ rejection in adult patients at mild to moderate immunological risk receiving an allogeneic renal or cardiac transplant and in adult patients receiving an allogeneic hepatic transplant (see section 4.4 special warnings and precautions for use).

Australia - engelsk - Department of Health (Therapeutic Goods Administration)

pharmacor pty ltd - everolimus, quantity: 0.25 mg - tablet, uncoated - excipient ingredients: butylated hydroxytoluene; lactose; ethanol absolute; hypromellose; magnesium stearate; lactose monohydrate; crospovidone; acetone - everolimus is indicated for the prophylaxis of organ rejection in adult patients at mild to moderate immunological risk receiving an allogeneic renal or cardiac transplant and in adult patients receiving an allogeneic hepatic transplant (see section 4.4 special warnings and precautions for use).

Australia - engelsk - Department of Health (Therapeutic Goods Administration)

pharmacor pty ltd - everolimus, quantity: 0.75 mg - tablet, uncoated - excipient ingredients: lactose monohydrate; lactose; crospovidone; butylated hydroxytoluene; magnesium stearate; acetone; ethanol absolute; hypromellose - everolimus is indicated for the prophylaxis of organ rejection in adult patients at mild to moderate immunological risk receiving an allogeneic renal or cardiac transplant and in adult patients receiving an allogeneic hepatic transplant (see section 4.4 special warnings and precautions for use).

Australia - engelsk - Department of Health (Therapeutic Goods Administration)

pharmacor pty ltd - everolimus, quantity: 1 mg - tablet, uncoated - excipient ingredients: lactose; crospovidone; lactose monohydrate; magnesium stearate; butylated hydroxytoluene; ethanol absolute; acetone; hypromellose - everolimus is indicated for the prophylaxis of organ rejection in adult patients at mild to moderate immunological risk receiving an allogeneic renal or cardiac transplant and in adult patients receiving an allogeneic hepatic transplant (see section 4.4 special warnings and precautions for use).

Australia - engelsk - Department of Health (Therapeutic Goods Administration)

pharmacor pty ltd - everolimus, quantity: 1 mg - tablet, uncoated - excipient ingredients: crospovidone; lactose; lactose monohydrate; magnesium stearate; ethanol absolute; acetone; hypromellose; butylated hydroxytoluene - everolimus is indicated for the prophylaxis of organ rejection in adult patients at mild to moderate immunological risk receiving an allogeneic renal or cardiac transplant and in adult patients receiving an allogeneic hepatic transplant (see section 4.4 special warnings and precautions for use).

USA - engelsk - NLM (National Library of Medicine)

hikma pharmaceuticals usa inc. - everolimus (unii: 9hw64q8g6g) (everolimus - unii:9hw64q8g6g) - everolimus is indicated for the prophylaxis of organ rejection in adult patients at low-moderate immunologic risk receiving a kidney transplant [see clinical studies (14.1)] . everolimus is to be administered in combination with basiliximab induction and concurrently with reduced doses of cyclosporine and with corticosteroids. therapeutic drug monitoring (tdm) of everolimus and cyclosporine is recommended for all patients receiving these products [see dosage and administration (2.2 and 2.3)] . everolimus is indicated for the prophylaxis of allograft rejection in adult patients receiving a liver transplant. everolimus is to be administered no earlier than 30 days posttransplant concurrently in combination with reduced doses of tacrolimus and with corticosteroids [see warnings and precautions (5.5) and clinical studies (14.2)] . tdm of everolimus and tacrolimus is recommended for all patients receiving these products [see dosage and administration (2.3, 2.5)] . the safety and efficacy of everolimus has not been